Results 91 to 100 of about 6,731 (217)
Platelet Inhibition in Percutaneous Coronary Interventions [PDF]
, 2018 : Mechanical disruption of atherosclerotic plaques at the time of percutaneous coronary intervention (PCI) is a potent stimulus for arterial thrombosis.
Roffi, Marco, Wyss, Christophe
core
Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study [PDF]
, 2010 Coronary artery disease (CAD) is believed to be the single leading cause of death in both men and women in the world. Smoking is the most important risk factor for CAD. Smoking increases platelet aggregation and thrombus formation. CD40 ligand (CD40L) is
Mehmet Kayrak +8 more
core +1 more source
Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Non-ST-Elevation Acute Coronary Syndromes [PDF]
, 1999 BACKGROUND: Glycoprotein (GP) IIb/IIIa receptor blockers prevent life-threatening cardiac complications in patients with acute coronary syndromes without ST-segment elevation and protect against thrombotic complications associated ...
Akkerhuis, K.M. (Martijn) +5 more
core
Cibles des médicaments antithrombotiques [PDF]
, 2006 Pour la quasi-totalité des classes thérapeutiques antithrombotiques actuellement utilisées et à venir, le ciblage a été initialement la conséquence d’une observation et non pas le fruit d’une recherche méthodique scientifique.
Drouet, Ludovic, Ripoll, Laurent
core +1 more source
Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes [PDF]
, 2015 OBJECTIVE: Acute coronary syndrome (ACS) encompasses ST segment elevation myocardial infarction (STEMI), with generally high thrombus burden and non-ST segment elevation ACS (NSTE-ACS), with lower thrombus burden.
Farag, M +3 more
core +1 more source
Eptifibatide-induced profound thrombocytopaenia: a rare complication
, 2021 Pranav Mahajan +3 more
openalex +2 more sources
Emerging drugs for sickle cell anemia. [PDF]
, 2015 INTRODUCTION: The search for effective therapeutic interventions for sickle cell disease (SCD) has been an ongoing endeavor for over 50 years. During this period, only hydroxyurea (HU), which received US FDA approval in February 1998, was identified as ...
Ballas, Samir K., Singh, Priya C
core +1 more source